arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BridgeBio Pharma, Inc.

BBIO

$84.47 ▲ +1.69 (+2.04%) at close

10 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

BridgeBio Pharma, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $16.2B

Dividend Yield —

Revenue Growth 126.3% ↘

Op. Margin -104.2% ↗

ROIC 660.7% ↗

FCF / Share $-2.33 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.96

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$502.08M

↑ +126.3% —

Net Income Profit after all expenses

$-732.94M

↓ -34.9% —

Operating Margin Operating profit as % of sales

-104.2%

↑ +61.0% 2th

FCF / Share Free cash flow per share

$-2.33

↑ +16.7% —

Long-Term Debt Long-term obligations

$2.01B

↑ +359.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	126.3% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1478%)	2285.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+28466%)	-88.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1200%)	11.4% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+42%)	745.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+9214%)	-79.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1096%)	—	—	—	—
EPS Growth YoY (%)	-31.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	27.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-21.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	16.4% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-34.9% Weak ↓ Weak Declining Year-over-year change in net income	16.8% Good ↑ Good Improving Year-over-year change in net income	-34.8% Weak ↓ Weak Declining Year-over-year change in net income	17.4% Good ↑ Good Improving Year-over-year change in net income	-16.0% Weak ↑ Weak Improving Year-over-year change in net income	-75.2% Weak ↑ Weak Improving Year-over-year change in net income	-70.3% Weak Weak Year-over-year change in net income	-286.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	16.7% Good ↑ Good Improving Year-over-year change in free cash flow	13.7% Fair ↑ Fair Improving Year-over-year change in free cash flow	-12.9% Weak Weak Year-over-year change in free cash flow	18.7% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	86.3% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	47.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	4.1% Caution Caution Compound annual revenue growth over 3 years	24.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	127.4% Excellent Excellent Compound annual revenue growth over 5 years	40.5% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	-104.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-795%)	-267.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1881%)	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
Profit Margin (%) (%)	-146.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1317%)	-244.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2140%)	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-89.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-235.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	660.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	57.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	66.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	49.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	103.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-247.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-39.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-40.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-55.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-64.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-111.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-82.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-67.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-39.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	35.1% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+134%)	37.0% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+147%)	48.2% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+222%)	38.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+158%)	67.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+349%)	—	-70.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-571%)	-53.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-459%)	-51.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-440%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	-0.96x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-260%)	-0.30x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-150%)	-0.33x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-155%)	-0.34x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-157%)	-0.49x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-182%)	1.62x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+170%)	0.23x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-61%)	0.17x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-71%)	—	—
Interest Coverage (x)	-11.99x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-17.27x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-17.74x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-6.37x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-12.33x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-12.94x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-30.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-72.11x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3373.69x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$1.44B	$-243.76M	$70.51M	$54.30M	$36.98M	$-262.20M	$-268.40M	$-381.58M	$-92.00M	—
Debt / EBITDA (x)	-3.88x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.75x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.74x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.85x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.75x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.20x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.36x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.30x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$2.62	$1.19	$0.06	$0.53	$0.48	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.78	$-2.88	$-3.95	$-3.26	$-3.90	—	—	—	—	—
Free Cash Flow per Share (USD)	$-2.33	$-2.80	$-3.25	$-2.88	$-3.54	—	—	—	—	—
Book Value per Share (USD)	$-10.71	$-7.72	$-7.73	$-8.33	$-5.91	$0.47	$3.30	$3.42	—	—
Tangible Book Value per Share (USD)	$-10.86	$-7.85	$-7.89	$-8.52	$-6.21	$0.47	$3.30	$3.42	—	—
Basic Weighted Avg Shares (shares)	191.53M	186.08M	162.79M	147.47M	144.36M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$509.78M	$566.29M	$333.75M	$427.43M	$753.79M	$547.18M	$508.24M	$412.65M	—	—
LT Debt (USD)	$2.01B	$437.34M	$446.44M	$430.99M	$430.75M	$93.88M	$95.37M	$54.51M	—	—
Total Equity (USD)	$-2.09B	$-1.47B	$-1.35B	$-1.25B	$-870.41M	$57.91M	$408.45M	$314.88M	$85.85M	$14.89M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$502.08M	$221.90M	$9.30M	$77.65M	$69.72M	$8.25M	$40.56M	—	—	—
Depreciation Expense (USD)	$5.43M	$6.08M	$6.49M	$6.77M	$5.84M	$1.46M	—	—	—	—
Net Income, GAAP (USD)	$-732.94M	$-543.35M	$-653.25M	$-484.65M	$-586.45M	$-505.49M	$-288.58M	$-169.45M	$-43.83M	—
Operating Cash Flow (USD)	$-445.91M	$-520.73M	$-527.72M	$-419.49M	$-497.93M	$-399.71M	$-253.59M	$-136.64M	$-40.49M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 34 quarters

BridgeBio Pharma, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BBIO with peers